Abstract:Transforming growth factor-β superfamily members, such as myostatin, growth/differentiation factor 11, and activin A, negatively regulate skeletal muscle mass. Inhibitors targeting these cytokines or activin receptor type IIB have the potential to treat muscular diseases and enhance physical performance. However, because of their effects on muscle mass and potential misuse, they are strictly prohibited in sports. Given the high potential for misuse as a doping agent in sports, effective analytical methods for these prohibited antibodies targeting these specific cytokines or their receptor are critically needed. In this study, we aimed to develop and validate a multitarget method to detect the prohibited transforming growth factor-β superfamily-targeting monoclonal antibodies, such as landogrozumab, domagrozumab, and the activin receptor type IIB-targeting antibody, bimagrumab, in human plasma and dried blood spot (DBS) samples using liquid chromatography-tandem mass spectrometry. Antibodies were purified from both the DBS and plasma samples using protein G magnetic beads and field-asymmetric ion mobility spectrometry (FAIMS) to minimize interference, followed by liquid chromatography-tandem mass spectrometry analysis. The validation process included tests for specificity, selectivity, linearity, limit of detection (LOD), limit of identification, precision, recovery, carryover effect, and matrix effect. The LODs for the target antibodies were identical in both DBS and plasma samples at 0.1 μg/mL for landogrozumab heavy and light chains, as well as 0.25 μg/mL for the domagrozumab light chain and 0.25 μg/mL for the bimagrumab heavy chain. However, the heavy chain of domagrozumab exhibited an LOD of 0.5 μg/mL in DBS and 1 μg/mL in plasma. The analytical method demonstrated strong linearity, with R2 values greater than 0.99 for both plasma and DBS, and no carryover effect. Precision (CV%) was below 15 % at both middle (1 or 5 μg/mL; specific to the heavy chain of domagrozumab in plasma) and high (10 μg/mL) concentrations and was less than 20 % at the LOD. The selectivity and specificity indicated no interference in the analysis of target mAbs in different blood samples. Recovery was 31.6–49.8 % for DBS and 51.4–85.3 % for plasma, with no significant matrix effect. This study provides an effective method for doping analysis and novel protein detection.

High-Throughput Equine Doping Controls on a Trapped Ion Mobility Quadrupole-Time-of-Flight Mass Spectrometer: Technical Considerations of dia/slice/prmPASEF Applied to the Long-Term Detection of Monoclonal Antibodies

Efficient use of retention time for the analysis of 302 drugs in equine plasma by liquid chromatography-MS/MS with scheduled multiple reaction monitoring and instant library searching for doping control

A steroidomic approach for biomarkers discovery in doping control

A Broad-Spectrum Peptide Screening Method Using an Optimized Solid-Phase Extraction and Liquid Chromatography–High-Field Asymmetric Ion Mobility Spectrometry–Mass Spectrometry for Doping Control in Equine Urine

diaPASEF Enables High-throughput Proteomic Analysis of Host Cell Proteins for Biopharmaceutical Process Development

Quantification of 782 Plasma Peptides by Multiplexed Targeted Proteomics

Development of two complementary LC-HRMS methods for analyzing sotatercept in dried blood spots for doping controls

P28-S Digging Deeper and Faster into Proteome by IgY-Immunoaffinity Fractionation

Development and validation of general plasma screening method for performance enhancing drugs in racehorses utilizing liquid chromatography-high-resolution mass spectrometry (LC-HRMS)

A Multi-Class, Multi-Residue Method for Detection of Veterinary Drugs in Multiple Meat Using a Pass-Through Cleanup SPE Technique and UPLC-MS/MS Analysis

Quick and High-Throughput Quantification of Β-Agonists Residues in Animal-Derived Foods Using Enzymatic Probe Sonication Coupled with Automatic Solid-Phase Extraction

Non-Targeted Detection of Synthetic Oligonucleotides in Equine Serum Using Liquid Chromatography–High-Resolution Mass Spectrometry

Differential Mobility Spectrometry Coupled with Multiple Ion Monitoring in Regulated LC-MS/MS Bioanalysis of a Therapeutic Cyclic Peptide in Human Plasma

Progress in Targeted Mass Spectrometry (parallel Accumulation-Serial Fragmentation) and Its Application in Plasma/Serum Proteomics.

Screening in veterinary drug analysis and sports doping control based on full-scan, accurate-mass spectrometry

Detection and quantitation of host cell proteins in monoclonal antibody drug products using automated sample preparation and data-independent acquisition LC-MS/MS

Data Independent Acquisition to Inform the Development of Targeted Proteomics Assays Using a Triple Quadrupole Mass Spectrometer

Multi attribute method implementation using a High Resolution Mass Spectrometry platform: From sample preparation to batch analysis

Simultaneous detection of myostatin-targeting monoclonal antibodies in dried blood spots and plasma using liquid chromatography-tandem mass spectrometry with field asymmetric ion mobility spectrometry

Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring

Doping control analysis of myo‐inositol trispyrophosphate and 10 bisphosphonates in equine plasma by ion chromatography–mass spectrometry and its application to clodronic acid horse administration